Available Technologies

ADDITIONAL FILTERS

295 available technologies

FEATURED TECHNOLOGY

Human Monoclonal Antibodies to Infectious Diseases

Using human B cell hybridoma creation, and antibody engineering technologies, Dr. James E Crowe Jr.'s laboratory has developed an array of antibodies from full length human antibodies to Fab fragments and diabodies. Many of these antibodies are ready for a cooperate partner who can further develop these antibodies into biologic herapeutics. The table below is a sample of the antibodies they are currently researching and have available. In addition to these areas of research, Dr. Crowe is actively seeking collaborative opportunities to identify new interesting targets for future antibody engineering projects.
FEATURED TECHNOLOGY

Molecular Profiles for Subtyping Triple Negative Breast Cancer

Personalized medicine is at the forefront of medical news and specialized diagnostics that can align patients with the correct treatment are the key to this type of medicine. Jennifer Pietenpol and colleagues have performed extensive research and discovered that triple negative breast cancer (TNBC) is a heterogeneous disease with at least six subtypes. These subtypes have differing biological behaviors and sensitivities to known therapeutics. Diagnostic assays will help guide personalized and more effective therapy.
FEATURED TECHNOLOGY

Serotonin 2B Receptor Antagonism to Prevent Heart Valve Disease

Vanderbilt researchers have developed a novel approach that could potentially prevent or slow the progression of DAVD at its earliest possible stages so as to greatly increase patient quality of life. The initial mechanism which triggers fibrotic lesion formation occurs by phenotypic modulation of the aortic valve interstitial cells (AVICs) to the constitutive myofibroblast phenotype, producing significant amounts of extracellular matrix, similar to fibrotic remodeling in other tissues. Thus, desired goal to prevent DAVD is to control the phenotype modulation by specifically inhibiting molecular mechanisms that are known to cause activation of AVICs. This is achieved by inhibiting transforming growth factor-
FEATURED TECHNOLOGY

Assays to detect Cox-2 activity for determining treatment effectiveness for a variety of inflammatory and cancerous diseases

This invention identifies COX-2 metabolites as markers for a variety of inflammatory, neurodegenerative and cancerous diseases, and it provides a means for determining and monitoring levels of metabolites of COX-2 from patient samples. It may also be used to augment information from imaging and other diagnostic and disease progression monitoring modalities. In addition, the technology provides a means for testing activity of agonists or antagonists that can aid in the design of drugs that reduce effects of harmful prostaglandins with reduced side effects.
FEATURED TECHNOLOGY

Multisubstrate Inhibitors of Histone Acetylation Increase the Cytotoxicity of Chemotherapeutic Agents

Inhibitors of histone acetylation may constitute a novel class of potent therapy sensitizers applicable to a broad range of conventional cancer treatments.
FEATURED TECHNOLOGY

Modified Auditory and Visual EndovasculaR/IntracardiaC Catheter (MAVERICC)

'Coffee Ring' Diagnostic for Point-of-Care Biomarker Detection

Bright minds at Vanderbilt University have unveiled a breakthrough technology that could bring sophisticated biomarker diagnostics to the developing world. The point-of-care diagnostic is designed to be used in the field; no specialized equipment, expertise, or white lab coats are required. The diagnostic is based upon the ingenous observation that evaporating liquid droplets leave behind a characteristic ring pattern, which may be familiar to our readers in the form of a coffee-ring stain.

Mammalian Genes Involved in Infection

OLINDA/EXM Radiation Dose Assessment Software Application (FDA Approved)

The OLINDA/EXM® personal computer code performs dose calculations and kinetic modeling for radiopharmaceuticals (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling). OLINDA® calculates radiation doses to different organs of the body from systemically administered radiopharmaceuticals and performs regression analysis on user-supplied biokinetic data to support such calculations for nuclear medicine drugs. These calculations are used to perform risk/benefit evaluations of the use of such pharmaceuticals in diagnostic and therapeutic applications in nuclear medicine. The technology employs a number of standard body models for adults, children, pregnant women and others, that are widely accepted and used in the internal dose community. The calculations are useful to pharmaceutical industry developers, nuclear medicine professionals, educators, regulators, researchers and others who study the accepted radiation doses that should be delivered when radioactive drugs are given to patients or research subjects.

Catheter Having Temperature Controlled Anchor and Related Methods

Heart valve disease is the 3rd most prevalent source of cardiovascular disease, leading to approximately 20,000 deaths per year in the U.S. alone. Moreover, there are an estimated 41,000 mitral valve procedures performed in the U.S. each year. The only effective, long-term treatment for mitral valve disease is open-chest valve replacement surgery, which is highly undesirable for elderly patients. Thus, there is a pressing need to develop novel percutaneous strategies for treatment that will reduce the number of open-chest surgeries. David Merryman and colleagues have developed a new, combined catheter that uses cryo temperatures to adhere to moving mitral valve leaflets and radiofrequency ablation to alter the compliance of the leaflet tissue to prevent prolapse and regurgitation.

A Novel Method for Importing Peptides with Functional Cargo Into the Cells

This technology enables the delivery of biological molecules into the interior of a cell. Such a delivery mechanism could be utilized in a variety of therapies including peptide, gene transfer and/or antisense therapy.

Bioprocess Technology for Synthesis of Chiral Compounds

Commercial routes to industrially important pharmaceutical and agrichemical compounds can often be developed more economically when separation of enantiomeric intermediates/ products is possible. Vanderbilt University seeks to license technologies, originally invented at DuPont, that allow such separations to be performed via novel biocatalysts. Vanderbilt's technology can be used for the production of chiral tertiary esters and/ or enantiomeric amides. In the case of the former class of compounds, our technology is somewhat unique in its ability to operate on carbonyl groups alpha to a tertiary center. See the following description for more information about the current status of this technology and the associated patent estate.

Vanderbilt Performance Evaluation System (VPES) & Job Descriptions Database

Vanderbilt University Medical Center (VUMC) job performance evaluations are part of an annual cycle called performance development in which supervisors and staff members identify and tackle specific job goals with close attention given to the VUMC mission, credo and job descriptions. Many hospital systems, including VUMC, now desire to base annual salary increases largely on performance evaluation ratings. VPES and the Job Description Database allow performance evaluations to be applied consistently and efficiently across the organization.

Featured Video

2012 Highlights

A motion graphic video describing operational improvements and successes of FY2012. Click here for a full PDF report.